Compare CION & PACB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CION | PACB |
|---|---|---|
| Founded | 2011 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Laboratory Analytical Instruments |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 344.9M | 419.8M |
| IPO Year | 2011 | 2010 |
| Metric | CION | PACB |
|---|---|---|
| Price | $7.39 | $1.59 |
| Analyst Decision | Sell | Hold |
| Analyst Count | 1 | 3 |
| Target Price | ★ $7.00 | $1.67 |
| AVG Volume (30 Days) | 618.5K | ★ 5.5M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | ★ 16.44% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $93,468,000.00 |
| Revenue This Year | N/A | $11.32 |
| Revenue Next Year | N/A | $12.13 |
| P/E Ratio | $17.55 | ★ N/A |
| Revenue Growth | N/A | ★ 3.04 |
| 52 Week Low | $6.50 | $0.85 |
| 52 Week High | $10.93 | $2.73 |
| Indicator | CION | PACB |
|---|---|---|
| Relative Strength Index (RSI) | 54.50 | 59.92 |
| Support Level | $6.55 | $1.52 |
| Resistance Level | $10.21 | $1.64 |
| Average True Range (ATR) | 0.23 | 0.10 |
| MACD | 0.11 | 0.04 |
| Stochastic Oscillator | 96.25 | 93.59 |
CION Invt Corp is an externally managed, non-diversified, closed-end management investment company that has elected to be regulated as a business development company. The Companies portfolio is comprised of investments in senior secured debt, including first lien loans, second lien loans, and unitranche loans, and, to a lesser extent, collateralized securities, structured products and other similar securities, unsecured debt, and equity, of private and thinly-traded U.S. middle-market companies. Its investment objective is to generate current income and, to a lesser extent, capital appreciation for investors.
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Europe Middle East, and Africa and Asia-Pacific.